HF TREATMENT PROGRESS
|
|
- Alyson Dennis
- 6 years ago
- Views:
Transcription
1 Mortality Digoxin, Diuretics, Hydralazi ne HF TREATMENT PROGRESS SOLVD CONCENSUS -16 to -31 % + ACE-I CIBIS II COPERNICUS -35 % + b- blockers RALES -22 % COMPANION & CARE HF -36 % + Aldostero ne Inhibitors + CRT-ICD Ellenbogen KA, J Am Coll Cardiol 2005; 46:
2 The new Heart Failure Paradox Striking improvements in the prognosis of individual cardiac conditions (ACS, severe hypertension, valvular and congenital heart disease) but growing prevalence of heart failure. Braunwald E. JACC Heart Failure 2013: 1: 1-20
3 US: Discharges from HF hospitalization Braunwald E. JACC Heart Failure 2013: 1: 1-20
4 Laribi S, et al. Eur J Heart Fail 2012;14:234-9
5 IN-HF Outcome 1-year all-cause mortality Worsening HF: 27.7% De Novo HF: 19.2% Chronic HF: 5.9% Days from enrollment Tavazzi L, et al Circ Heart Fail. 2013;6:
6 Evidence-Based Heart Failure RCTs: All Pharmacologic Therapies have Focused on Neurohormonal Blockade HFrEF V-HeFT CONSENSUS SOLVD SAVE RALES CIBIS-2 MERIT-HF COPERNICUS Val-HeFT CHARM EPHESUS SHIFT EMPHASIS ACEis MRAs Beta-Blockers ARB IVABRADINE
7 Ivabradine Overview
8
9 Recent Strategies in Heart Failure Therapy Inotropic Diuretic Substituting Hormonal Anti inflammatory Anti neurohormonal?
10 Recent Strategies in Heart Failure Therapy HR lowering CRT Mitra Clip Telemonitoring?
11 Primary composite endpoint Ivabradine n=793 (14.5%PY) Placebo n=937 (17.7%PY) Cumulative frequency (%) HR = 0.82 [95% CI ] p< NNT 1 year = 26-18% 10 Ivabradine Placebo Months
12 Primary composite endpoint according to HR achieved at day 28* Patients with primary composite endpoint (%) bpm 70-<75 bpm 60-<65 bpm 65-<70 bpm <60 bpm Day Months *Data exclude patients reaching primary composite endpoint in the first 28 days
13 LV End Diastolic Volume Index LVEDVI (ml/m 2 ) 100 DD-5.5; p = D -7.9 ml/m 2 D -1.8 ml/m Baseline M 8 Ivabradine (n=204) Baseline M 8 Placebo (n=199) Tardif JC et al. Eur Heart J 2011;32(20):
14 LV End Systolic Volume Index Primary endpoint LVESVI, ml/m 2 75 DD= -5.8; p = D ml/m 2 D ml/m Baseline M 8 Ivabradine (n=208) Baseline M 8 Placebo (n=203) Tardif JC et al. Eur Heart J 2011;32(20):
15 LV Ejection Fraction LVEF (%) ± 29.1 DD= 2.7; p = D = +2.4 % D = % Baseline M 8 Ivabradine (n=204) Baseline M 8 Placebo (n=199) Tardif JC et al. Eur Heart J 2011;32(20):
16
17
18
19
20
21 Heart Rate reduction is a positive inotropic intervention in HF!!
22 Force- Frequency Relationship Human Papillary Muscle Strips NF NYHA IV Frequency (Hz) Böhm M, et al. Clin Invest. 1992;70:
23 Recent Strategies in Heart Failure Therapy Inotropic Diuretic Substituting Hormonal Anti inflammatory Anti neurohormonal?
24 Ivabradine Overview
25 (pg/ml) BNP Levels Class I Class II Class III Class IV
26 Nesiritide
27
28 Neprilysin (neutral endopeptidase 24.11; NEP) is responsible for NP degradation Metabolism of ANP and other peptide hormones by NEP NEP is the major enzyme responsible for degrading the NPs (ANP, BNP, CNP) 1,3-5 ANP + NEP enzyme NEP catalyzes the degradation of other vasoactive peptides: vasodilating peptides substance P 6 NPR-C NPR-A Inactive fragments bradykinin 1 Clearance of ANP Guanylate cyclase GTP cgmp Diuresis Natriuresis Vasodilation Antiproliferative/ antihypertrophic 28
29 Neprilysin (neutral endopeptidase 24.11; NEP) is responsible for NP degradation Metabolism of ANP and other peptide hormones by NEP 1,2,8,9 ProEndothelin + + Endothelin (ET1) Inactive fragments NEP is the major enzyme responsible for degrading the NPs (ANP, BNP, CNP) 1,3-5 NPR-C Clearance of ANP GTP ANP + NPR-A Guanylate cyclase Inactive fragments cgmp NEP enzyme Ang II Substance P Bradykinin Adrenomedullin Diuresis Natriuresis Vasodilation Antiproliferative/ antihypertrophic + NEP catalyzes the degradation of other vasoactive peptides: vasodilating peptides substance P 6 bradykinin 1 vasoconstrictor peptides ET-1 7 Ang II 1 NEP converts big ET-1 to the active vasoconstrictor peptide ET Erdos, Skidgel. FASEB J 1989;3:145 51; 2. Levin et al. N Engl J Med 1998;339;321 8; 3. Stephenson et al. Biochem J 1987;243:183 7; 4. Lang et al. Clin Sci 1992;82:619 23; 5. Kenny et al. Biochem J 1993;291:83 8; 6. Skidgel et al. Peptides 1984;5: Abassi et al. Metabolism 1992;41:683 5; 8. Murphy et al. Br J Pharmacol 1994;113: Jiang et al. Hypertens Res 2004;27:109 17
30 Neprilysin inhibition enhances the effects of NPs Metabolism of ANP and other peptide hormones by NEP NPR-C Clearance of ANP GTP ProEndothelin ANP NPR-A Guanylate cyclase Inactive fragments cgmp Endothelin (ET1) NEP enzyme Inactive fragments Ang II Substance P Bradykinin Adrenomedullin Diuresis Natriuresis Vasodilation Antiproliferative/ antihypertrophic 1. Erdos, Skidgel. FASEB J 1989;3:145 51; 2. Levin et al. N Engl J Med 1998;339;321 8; 3. Murphy et al. Br J Pharmacol 1994;113:137 42; 4. Jiang et al. Hypertens Res 2004;27:109 17; 5. Ferro et al. Circulation 1998;97: ; 6. Martinez-Rumayor et al. Am J Cardiol 2008;101[suppl]:3A-8A; 7. Richards et al. J Hypertens 1993;11: Neprilysin (NEP) is the major enzyme responsible for degrading NPs 5 BNP, not NT-proBNP, is a NEP substrate 6 Inhibition of NEP enhances the effects of NPs 7 Studies suggest the potential effects of NEP inhibitors may be offset by an increase in Ang II levels 2,5,7
31 Neprilysin has many substrates that are metabolized with differing levels of affinity Metabolism of natriuretic and other vasoactive peptides* by NEP 1 9 Implications for NEP inhibition Relative affinity for NEP ANP and CNP Ang II Ang I NEP substrates can have opposing biological actions 10 Overall effect is dependent upon the net effect on NEP metabolism of individual substrates 10 Adrenomedullin Substance P Bradykinin Endothelin NEP Inactive fragments or metabolites Benefits in enhancing NP system may be offset by increased Ang II 11 Needs to be complemented by simultaneous RAAS suppression 2,11,12 BNP *Not an exhaustive list of all neprilysin substrates; the most relevant substrates for cardiovascular physiology are listed Ang=angiotensin; ANP=atrial natriuretic peptide; BNP=B-type natriuretic peptide; CNP=C-type natriuretic peptide; NEP=neprilysin; NP=natriuretic peptide; RAAS=renin angiotensin aldosterone system 1. Erdos, Skidgel. FASEB J 1989;3:145 51; 2. Levin et al. N Engl J Med 1998;339;321 8; 3. Stephenson et al. Biochem J 1987;243:183 7; 4. Lang et al. Clin Sci 1992;82:619 23; 5. Kenny et al. Biochem J 1993;291:83 8; 6. Skidgel et al. Peptides 1984;5:769 76; 7. Abassi et al. Metabolism 1992;41:683 5; 8. Murphy et al. Br J Pharmacol 1994;113:137 42; 9. Jiang et al. Hypertens Res 2004;27:109 17; 10. Langenickel & Dole. Drug Discovery Today: Ther Strateg 2012;9:e131 9; 11. Richards et al. J Hypertens 1993;11:407 16; 12. Ferro et al. Circulation 1998;97:
32 OMAPATRILAT
33
34 Packer M et al, Circulation 2002;106:920.26
35 In OCTAVE ( hypertensive ) angioedema was more frequent with omapatrilat than enalapril (2.17% v 0.68%).
36
37 LCZ696 First in Class Dual-acting Angiotensin Receptor Neprilysin Inhibitor LCZ696 is a crystalline complex comprised of 6 valsartan moieties, 6 sacubitril (AHU377) moieties, sodium cations, and water held together by network of hydrogen bonds Sacubitril Valsartan in LCZ696 is present in anionic form, and is thus more biovailable than in valsartan as a free acid. 200 mg of LCZ696 is equivalent to 160 mg of standard valsartan Valsartan
38
39 BNP is formed by cleavage of precursor molecules 1 6 Pre-proBNP probnp (aa1-aa108) NP effects include 7,8 : Wall stress NT-proBNP (aa1-aa76) Cleavage DPP-IV BNP 1 32 (aa77-aa108) Meprin A vasodilation blood pressure sympathetic tone aldosterone levels natriuresis diuresis fibrosis hypertrophy NPs are degraded by NEP. 9 Therefore, NP effects can be enhanced by inhibiting NEP BNP 3 32 BNP Martinez-Rumayor et al. Am J Cardiol 2008;101[suppl]:3A 8A; 2. Daniels, Maisel. J Am Coll Cardiol 2007:50: ; 3. Melanson, Lewandrowski. Am J Clin Pathol 2005;124:S122 8; 4. Ichiki, Burnett. Circulation 2010;122:229 32; 5. De Palo et al. Clin Chem 2000;46:843 7; 6. Ruskoaho. Endocrine Rev 2003;24:341 56; 7. Levin et al. N Engl J Med 1998;339;321 8; 8. Nathisuwan, Talbert. Pharmacotherapy 2002;22:27 42; 9. Erdos, Skidgel. FASEB J 1989;3:145 51
40
41 PARADIGM-HF tre first time For the first time after many years a new drug reduces mortality in HF For the first time an hormonal substituting drug appears clinically effective For the first time a trial does not add a new drug on top of the list but substitutes one of the standard molecules
42
43 PARADIGM-HF: Baseline characteristics Baseline characteristic SOLVD-T N=2569 CHARM- Added N=2548 HEAAL a N=3834 RAFT N=17 98 SHIFT N=650 5 EMPHASIS -HF N=2737 PARADIGM -HF N=8442 Mean age, years Women, % NYHA class, % I II III IV Race, % White Black Asian Other Mean heart rate, bpm Mean blood pressure, mmhg Systolic Diastolic Mean LVEF, % Mean QRS duration, ms Mean BMI, kg/m Ischemic etiology, % a Median; McMurray et al. Eur J Heart Fail. 2014;16:
44 The PARADIGM patients on Enalapril 1-yr CV mortality 8% 1-yr CV death or hospitalization 15%
45 PARADIGM-HF: Patient disposition 10,513 patients entered enalapril run-in phase (median duration, 15 days; interquartile range [IQR], 14 21) 9419 entered LCZ696 run-in phase (median duration, 29 days; IQR, 26 35) 8442 underwent randomization 1102 discontinued study: 591 (5.6%) had adverse event 66 (0.6%) had abnormal laboratory or other test result 171 (1.6%) withdrew consent 138 (1.3%) had protocol deviation, administrative problem or were lost to follow-up 49 (0.5%) died 87 (0.8%) had other reasons 977 discontinued study: 547 (5.8%) had adverse event 58 (0.6%) had abnormal laboratory or other test result 100 (1.1%) withdrew consent 146 (1.6%) had protocol deviation, had administrative problem, or were lost to follow-up 47 (0.5%) died 79 (0.8%) had other reasons 43 were excluded: 6 did not undergo valid randomization 37 were from four sites prematurely closed because of major Good Clinical Practice violations 4187 were assigned to receive LCZ had known final vital status 11 had unknown final vital status 4212 were assigned to receive enalapril 4203 had known final vital status 9 had unknown final vital status McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
46
47
48
49
50
51
52 Early Benefit of LCZ Months after Randomization Enalapril LCZ696
53 PARADIGM-HF: Absolute benefits Switching 1000 patients from an ACE inhibitor/arb to LCZ696 avoided: 47 primary endpoints 31 cardiovascular deaths 28 patients hospitalized for HF 37 patients hospitalized for any reason 53 admissions for HF 111 admissions for any reason over a median treatment period of 27 months Adapted from Packer M. et al., Circulation 2015
54 PARADIGM-HF a un anno dalla pubblicazione Nuovi risultati Timori Dati meccanicistici Riflessione sulla collocazione terapeutica
55 Alcuni timori PARADIGM-HF angioedema rischio competitivo fra mortalità e riospedalizzazione eccessiva preselezione nel run-in albuminuria e funzione renale Amyloid β Neoplasie mammarie e prostatiche
56 Event-free survival gain 1.3 yrs
57 Geometric Mean (nmol/l) Geometric Mean (pmol/l) Effect of LCZ696 vs Enalapril on Downstream Biomarkers cgmp Aldosterone Renin Period Enalapril Renin LCZ696 Renin Randomization Week Week 3 Week 4 Months 3 Week Week 3 Week 4 Months 3 Enalapril LCZ696
58 NT-proBNP pg/ml BNP pg/ml PARADIGM-HF: NT-proBNP and BNP NT-proBNP BNP Enalapril LCZ696 Months Adapted from Packer M. et al., Circulation 2015
59 Gori M et al, on behalf of the PARADIGM-HF Investigators ESC 2015
60 Gori M et al, on behalf of the PARADIGM-HF Investigators ESC 2015
61
62 PARADIGM-HF: Study design Single-blind active run-in period Randomization n=8442 Double-blind Treatment period Enalapril LCZ mg BID LCZ mg BID LCZ mg BID 10 mg BID* Enalapril 10 mg BID 2 Weeks 1 2 Weeks 2 4 Weeks ~34 months (event-driven) On top of standard HFrEF therapy (excluding ACEIs and ARBs) *Enalapril 5 mg BID (10 mg TDD) for 1 2 weeks followed by enalapril 10 mg BID (20 mg TDD) as an optional starting run-in dose for those patients who are treated with ARBs or with a low dose of ACEI; 200 mg TDD; 400 mg TDD; 20 mg TDD. McMurray et al. Eur J Heart Fail. 2013;15: ; McMurray et al. Eur J Heart Fail. 2014;16:
63
64 PARADIGM-HF may well represent a new threshold of hope for patients with HF Now, a novel drug, LCZ696, a dual inhibitor of angiotensin II receptor and neprilysin, may prove to be the first disruptive agent to the heart-failure treatment algorithm, which has remained essentially unchanged for a decade The beneficial results seen in PARADIGM-HF may apply to a wide spectrum of patients, even those who are currently receiving the best possible therapy Necessità di sorveglianza post marketing su effetti collaterali specifici Opportunità di trial dedicati allo scompenso cardiaco con FE preservata Jessup. N Engl J Med 2014; epub ahead of print: DOI: /NEJMe
65 Chronic Heart Failure Drug Therapy Diuretics, Ivabradine, Digitalis (ARB) ACE-I Nebivolol Carvedilol Bisoprolol Metoprolol Eplerenone Spirolonac.
66 Chronic Heart Failure Drug Therapy Diuretics, Ivabradine, Digitalis? LCZ 696 (ARNI) (ARB) ACE-I Nebivolol Carvedilol Bisoprolol Metoprolol Eplerenone Spirolonac.
67 Ivabradine Overview
68 PARADIGM PARAMETER PARAGON
69 The most stable PARADIGM patients 20 % of the most stable patients (no prior HF hospitalization) had a primary event 17 % died during the course of the trial In the most stable patients with a primary events, death occurred prior to a heart failure hospitalization in 51 % 60 % of these deaths were sudden cardiac deaths
70 FACTORS Associated with Noncompletion During the Run-in Period Prior to Randomization and the Efficacy of LCZ696 in the PARADIGM-HF Trial Desai A.S. et al., ESC 2015 Multivariable Predictors of Noncompletion Impact of LCZ696 vs. Enalapril on Clinical Outcomes, with IPW According to likelihood of randomization
71 Mortality HF TREATMENT PROGRESS Digoxin, Diuretics, Hydralaz ine SOLVD CONCENSUS -16 to -31 % CIBIS II COPERNICUS -35 % RALES -22 % + ACE-I + b- blockers + Aldostero ne Inhibitors COMPANION & CARE HF -36 % + CRT-ICD
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO Dario Leosco Università di Napoli Federico II Projected changes in cardiovascular diseases CVD Deaths Increase 33% CVD DALYS 22% CAD
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationNeurohormonal blockade: is there still room to go?
Neurohormonal blockade: is there still room to go? M.Birhan YILMAZ, MD, FESC, FACC, FHFA Professor of Cardiology, Cumhuriyet University Sivas, TURKEY President of Heart FailureWG of Turkish Society of
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationECG in CRT patients & novel HF therapies. Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος
ECG in CRT patients & novel HF therapies Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received grants from Medtronic Is identification
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationTerapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice
Terapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice Cattedra di Cardiologia Seconda Università di Napoli 60 CONGRESSO NAZIONALE SIGG NAPOLI, 25-28 NOVEMBRE
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationUNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE
UNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE By Mohammed Sadaka, MD ALEXANDRIA UNIVERSITY 2 Presentation Title Presenter Name Date Subject Business Use Only 1 HF is a complex syndrome involving multiple
More informationHFrEF and Neurohormonal Systems
HFrEF and Neurohormonal Systems Normal Control of the Circulation: Neurohumoral Balance Vasoconstrictor Salt and H 2 O retaining Vasodilator Diuretic Richard Troughton CSANZ Breakfast Symposium 15 June
More informationMEDICAL THERAPY IN HEART FAILURE
MEDICAL THERAPY IN HEART FAILURE Dr Lim Choon Pin MBBS, MRCP (UK), MMed (Int Med), FAMS, FESC, FACC Consultant Cardiologist, The Heart and Vascular Centre Heart Failure, Heart Transplant, Mechanical Circulatory
More informationFeast after Famine: The New Drugs for the Treatment of Heart Failure
Feast after Famine: The New Drugs for the Treatment of Heart Failure Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A., F.E.S.C. Medical Director, Advocate Medical Group-Midwest Heart Specialists Heart Failure
More informationImproving outcomes in heart failure with reduced EF
Improving outcomes in heart failure with reduced EF Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationL insuffisance cardiaque chez la personne âgée
L insuffisance cardiaque chez la personne âgée Congrès d automne de la SSMIG Berne, 14.09.2017 Prof. Dr. Jean-Michel Gaspoz Département de Médecine communautaire, de premier recours et des urgences Conflicts
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationRAAS blocker + B Blocker Troubleshooting
RAAS blocker + B Blocker Troubleshooting Heart Failure ECHO Clinic Virtual Heart Failure Consultation and Education Prof Ken McDonald & Dr. Patricia Campbell 13 th March 2017 HF activates 3 neurohormonal
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationSessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC
Sessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC J. Comin Colet Cap de Secció del Servei de Cardiologia i
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationChronic Heart Failure Therapies: Transforming the Landscape
Chronic Heart Failure Therapies: Transforming the Landscape Dr. Nadia Giannetti Chief of Cardiology Medical Director, Heart Failure and Heart Transplant Program McGill University Health Center Conflict
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationNew Pharmacological Developments In Heart Failure
New Pharmacological Developments In Heart Failure Diego Delgado, MD, FACC, MSc Associate Professor Site Director, Division of Cardiology Toronto General Hospital Heart Failure and Transplant Program University
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationDoes My Patient Always Require Diuretics???
Does My Patient Always Require Diuretics??? Shelley Zieroth, MD Associate Professor, Section of Cardiology Director, SBH Heart Failure and Transplant Clinics Head, Medical Heart Failure Program WRHA Cardiac
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationA New Future In Heart Failure (Should we reshuffle the deck?)
A New Future In Heart Failure (Should we reshuffle the deck?) DR. HEMANT SAHA, MD, MRCP(UK) AGA KHAN UNIVERSITY HOSPITAL, NAIROBI Disclosures Nothing to disclose. Objectives 1. Historical Perspectives
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationA new class of drugs for systolic heart failure: The PARADIGM-HF study
INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will describe the mechanism and use of angiotensin receptor-neprilysin inhibitors in heart failure MARWA A. SABE, MD, MPH Department of
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationPractical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece
Practical considerations for the use of ARNI in CHF: clinical cases J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Disclosures: Research grants and honoraria for lectures from
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than cancer
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 8 6 4 2 3.5 4.8 1. 1991 21 237 US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282,754 5-1% depending on severity
More informationSacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data,
Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data, praktische Erfahrungen michael.boehm@uks.eu M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin)
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationHeart Failure is the Fastest Rising Cardiovascular Condition in Canada. HF is a Progressive Condition with High Morbidity and.
Function & quality of life (QoL) Approved HF agents 1.Management of Heart Failure Patients in Ontario: Recommendations from Best Practice, April 213, *Ross et al. Treating the right patient at the right
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationHeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment?
HeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment? 08:00 Registra-on 08:25 Welcome and Thank You to Sponsors 08:30 09:15 10:00 10:30 The new kid on the block ARNI How do I effec-vely
More informationLearning Objectives. Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis
7:5 :5 am Update in Heart Failure SPEAKER Orly Vardeny, PharmD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Orly Vardeny, PharmD, MS: Advisory Board
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More information2017 ACC/AHA/HFSA HF guidelines. Advances in the Use of Biomarkers in Heart Failure Patients. Outline
Advances in the Use of Biomarkers in Heart Failure Patients Lori B. Daniels, MD, MAS, FACC, FAHA Professor of Medicine Director, Cardiovascular Intensive Care Unit Sulpizio Cardiovascular Center UC San
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationBeyond neuro-hormonal blockade
Beyond neuro-hormonal blockade Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective
ST2 as a Cardiovascular Biomarker Lori B. Daniels, MD, MAS, FACC Professor of Medicine Director, Coronary Care Unit University of California, San Diego ST2 and IL-33: Cardioprotective ST2: member of the
More informationBehandeling van Hartfalen: over 5 jaar
Behandeling van Hartfalen: over 5 jaar Adriaan Voors, cardioloog UMCG Over 5 jaar Heart Failure Treatment in 5 Years HFrEF: best evidence, biggest pipeline Entresto Omcamtiv LVAD: destination therapy HFrEF:
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationΝέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF).
Νέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF). ΧΑΡΑΛΑΜΠΟΣ Ι. ΚΑΡΒΟΥΝΗΣ Καθηγητής Καρδιολογίας Α.Π.Θ. Disclosures Teaching grants and honoraria
More informationWhat s new in Heart Failure care?
What s new in Heart Failure care? Prof Ahmet Fuat PhD FRCGP FRCP PG Dip (Cardiology) GP & GPSI Cardiology Darlington Professor of Primary Care Cardiology Durham University Acting Chair CVGP ESC guidelines
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More information